Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25680284 | 0.88 | LMNA (0.70) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL25680297 | 0.85 | LMNA (0.66) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL20511432 | 0.84 | LMNA (0.63) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL20510980 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL25680341 | 0.82 | AKR1C3 (0.64) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL25680349 | 0.81 | SMN1; SMN2 (0.61) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL20510985 | 0.80 | LMNA (0.62) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL20511302 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL25680337 | 0.80 | AKR1C3 (0.61) | LMNASMN1; SMN2MAPTHPGDTSHR | |
| SCHEMBL25680404 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | IAPP, GPR119, PNLIP | LMNA 4022/4885SMN1; SMN2 4513/4885MAPT 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.